期刊文献+

Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis 被引量:3

Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis
下载PDF
导出
摘要 BACKGROUND Recent evidence indicates that malignant ascites may be associated with the high malignancy and poor prognosis of gastric cancer(GC)with peritoneal metastasis(PM),but no robust consensus has been reached until now.AIM To evaluate the prognostic significance of malignant ascites in GC patients with PM.METHODS Two independent authors conducted database searches.The searches were performed in the EMBASE,PubMed,and Cochrane Library databases,and the terms used to search included stomach neoplasms,GC,ascites,peritoneal effusion,survival,and survival analysis.Outcomes included overall survival and hazard ratios with 95%confidence intervals(CIs).Three pairs of comparisons for measuring survival were made:(1)Patients with ascites vs those without ascites;(2)Patients with massive ascites vs those with mild to moderate ascites;and(3)Patients with massive ascites vs those with no to moderate ascites.RESULTS Fourteen articles including fifteen studies were considered in the final analysis.Among them,nine studies assessed the difference in prognosis between patients with and without malignant ascites.A pooled HR of 1.63(95%CI:1.47-1.82,P<0.00001)indicated that GC patients with malignant ascites had a relatively poor prognosis compared to patients without ascites.We also found that the prognosis of GC patients with malignant ascites was related to the volume of ascites in the six other studies.CONCLUSION GC patients with malignant ascites tend to have a worse prognosis,and the volume of ascites has an impact on GC outcomes. BACKGROUND Recent evidence indicates that malignant ascites may be associated with the high malignancy and poor prognosis of gastric cancer(GC) with peritoneal metastasis(PM), but no robust consensus has been reached until now.AIM To evaluate the prognostic significance of malignant ascites in GC patients with PM.METHODS Two independent authors conducted database searches. The searches were performed in the EMBASE, Pub Med, and Cochrane Library databases, and the terms used to search included stomach neoplasms, GC, ascites, peritoneal effusion, survival, and survival analysis. Outcomes included overall survival and hazard ratios with 95% confidence intervals(CIs). Three pairs of comparisons for measuring survival were made:(1) Patients with ascites vs those without ascites;(2) Patients with massive ascites vs those with mild to moderate ascites; and(3)Patients with massive ascites vs those with no to moderate ascites.RESULTS Fourteen articles including fifteen studies were considered in the final analysis.Among them, nine studies assessed the difference in prognosis between patients with and without malignant ascites. A pooled HR of 1.63(95%CI: 1.47-1.82, P <0.00001) indicated that GC patients with malignant ascites had a relatively poor prognosis compared to patients without ascites. We also found that the prognosis of GC patients with malignant ascites was related to the volume of ascites in the six other studies.CONCLUSION GC patients with malignant ascites tend to have a worse prognosis, and the volume of ascites has an impact on GC outcomes.
出处 《World Journal of Clinical Cases》 SCIE 2019年第20期3247-3258,共12页 世界临床病例杂志
基金 Supported by the National Natural Science Foundation of China,No.81672577
关键词 STOMACH NEOPLASMS PERITONEAL METASTASIS ASCITES Prognosis META-ANALYSIS Stomach neoplasms Peritoneal metastasis Ascites Prognosis Meta-analysis
  • 相关文献

参考文献2

二级参考文献22

  • 1P. Wimberger,H. Gilet,A-K. Gonschior.Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Annals of Oncology . 2012
  • 2Kuniaki Shirao,Narikazu Boku,Yasuhide Yamada,Kensei Yamaguchi,Toshihiko Doi,Masahiro Goto,Junichiro Nasu,Tadamichi Denda,Yasuo Hamamoto,Atsuo Takashima,Haruhiko Fukuda,Atsushi Ohtsu,Akira Sawaki,Hogara Nishisaki,Kenji Amagai,Yasuyuki Suzuki.Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106)[J]. Japanese Journal of Clinical Oncology . 2013 (10)
  • 3Tom Waddell,Ian Chau,David Cunningham,David Gonzalez,Alicia Frances,Clare Okines,Andrew Wotherspoon,Claire Saffery,Gary Middleton,Jonathan Wadsley,David Ferry,Wasat Mansoor,Tom Crosby,Fareeda Coxon,David Smith,Justin Waters,Timothy Iveson,Stephen Falk,Sarah Slater,Clare Peckitt,Yolanda Barbachano.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 4Donald Richards,Darren M. Kocs,Alexander I. Spira,A. David McCollum,Sami Diab,Lanny I. Hecker,Allen Cohn,Feng Zhan,Lina Asmar.Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomized phase 2 study[J].European Journal of Cancer.2013
  • 5T. Waddell,M. Verheij,W. Allum,D. Cunningham,A. Cervantes,D. Arnold.Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up[J].European Journal of Surgical Oncology.2014(5)
  • 6Joji Kitayama,Hironori Ishigami,Hironori Yamaguchi,Hiroharu Yamashita,Shigenobu Emoto,Shoich Kaisaki,Toshiaki Watanabe.Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites[J]. Annals of Surgical Oncology . 2014 (2)
  • 7T. Yamao,Y. Shimada,K. Shirao,A. Ohtsu,N. Ikeda,I. Hyodo.Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria. Japanese Journal of Clinical Oncology . 2004
  • 8Lin Shen,Jin Li,Jianming Xu,Hongming Pan,Guanghai Dai,Shukui Qin,Liwei Wang,Jinwan Wang,Zhenzhou Yang,Yongqian Shu,Ruihua Xu,Lei Chen,Yunpeng Liu,Shiying Yu,Lilian Bu,Yongzhe Piao.Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J]. Gastric Cancer . 2015 (1)
  • 9Simon C. Blackburn,Michael P. Stanton.Anatomy and physiology of the peritoneum[J]. Seminars in Pediatric Surgery . 2014 (6)
  • 10Nian Fang,Hui-Qing Zhang,Bo He,Mei Xie,Shan Lu,Yi-Ye Wan,Nong-Rong Wang.Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites[J]. Tumor Biology . 2014 (4)

共引文献29

同被引文献39

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部